ALX Oncology Holdings Inc. (ALXO) Financials

ALXO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 178.3 million 27.0 million
Dec. 31, 2025 59.0 million 33.1 million
Sept. 30, 2025 82.7 million 37.9 million
June 30, 2025 95.3 million 30.9 million

ALXO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -18.7 million 2.5 million
Dec. 31, 2025 -19.0 million 2.7 million
Sept. 30, 2025 -17.1 million 2.5 million
June 30, 2025 -23.5 million 2.1 million

ALXO Net Income

No data available :(

ALXO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 140.3 million - -
Dec. 31, 2025 44.8 million - -
Sept. 30, 2025 60.6 million - -
June 30, 2025 79.3 million 7.0 million 6.1 million

ALXO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 54.3 million
Dec. 31, 2025 54.3 million
Sept. 30, 2025 53.6 million
June 30, 2025 53.4 million

ALXO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 50000 13.6 million 5.4 million -
Dec. 31, 2025 49000 17.6 million 5.4 million -
Sept. 30, 2025 56000 17.4 million 5.1 million -
June 30, 2025 47000 18.0 million 5.5 million -

ALXO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 150000
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - 191000

ALXO

Price: $1.38

52 week price:
0.40
2.66

Earnings Per Share: -1.49 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 63179

Market Capitalization: 211.9 million

Links: